(Reuters) - Pfizer filed an antitrust lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for biotech Metsera to stall, not close, the deal, a tactic it said is ...

Pfizer is playing catch-up in the GLP-1 weight-loss space. The drugmaker is getting closer and closer to key patent cliffs. Investors should also note that Pfizer's payout ratio is worryingly high.

Novo Nordisk’s CEO dared Pfizer to bid more if it wanted obesity drug developer Metsera so badly. So Pfizer did, with a $10 billion bid that edges out what the Danish pharmaceutical giant was willing ...

A former executive at companies like Syndax Pharmaceuticals, AstraZeneca and Pfizer has landed a new funding round for his latest venture.